Towa Pharmaceutical Co., Ltd. - Acquisition of Spain’s Pensa Investments, S.L.
Leading Japanese law firm Nishimura & Asahi advised Towa Pharmaceutical Co., Ltd. [TSE: 4553], a Japanese generic drug company, on its acquisition of Pensa Investments, S.L., the generics division of Spanish pharmaceutical companies Corporación Químico Farmacéutica Esteve, S.A. and Esteve Pharmaceuticals, S.A., in an all-cash deal for EUR 320 million.
The Nishimura & Asahi team advising Towa Pharmaceutical was led by partners Yoshinobu Fujimoto, Yoshiyuki Kizu and Dominik Kruse, supported by Mihoko Hori, Daisuke Hoshino, Junko Wakabayashi, Satoshi Aizawa and James Campbell.
People
Yoshi’s practice covers various M&A transactions, cross border deals, and day-to-day commercial businesses, with a focus on Europe-related matters. He lived in Europe approx. 8 years including studying at the master of law at UCL in London, working approx. 3 years in leading firms in Frankfurt, Paris and Italy, a short secondment in Barcelona/Madrid and having regular business trips all across Europe including the Netherlands, Nordic countries and Eastern Europe. As a leading partner of Europe practice and cross-border team, Yoshi provides a tailored legal services in a timely and flexible manner.
Dominik serves as co-representative of our offices in Frankfurt and Düsseldorf, Germany. He advises Japanese companies on corporate and cross-border M&A matters, as well as European companies regarding their business expansion into Southeast Asia (notably Indonesia, Thailand and Vietnam). He has a wealth of international experience and brings unique insights into deal-making across different cultures in both emerging and mature markets. Before joining the Tokyo office of Nishimura & Asahi in November 2019, Dominik worked at Clifford Chance (based out of Düsseldorf, Germany, and New York) and as in-house counsel at Pfizer, Inc. (New York).
Yoshinobu was promoted to partner in 1999. He has experience in NP loans, real estate transactions, and equity investment cases dealing with foreign capital funds and companies. In addition to domestic M&A and business integration cases, he has recently been engaged in many M&A and JV cases by Japanese corporations in the USA, Europe, and Asian countries. He has advised Japanese corporations on lawsuits in the USA and other overseas countries, and has extensive experience in the dispute settlement and risk management fields. He has won many awards in the Corporate/M&A, Private Wealth and Healthcare fields from business law reviews, such as Chambers Global and The Legal 500 Asia-Pacific.